FDA's docket FDA-2026-N-7542 asked for input on provider training and credentialing, patient safety, access, and data standardization for psychedelics used in supervised settings. The notice says, in writing, that scheduling under the Controlled Substances Act, legalization, and the safety or efficacy of any particular product are out of scope. So a comment filing — including MAPS's, whose contents are behind a password and therefore unverifiable — moves the standards conversation, not the legal status of anything. Meanwhile the thing that could actually change access is Compass Pathways' rolling NDA for COMP360 psilocybin, which the company's own SEC filing says must be rescheduled by DEA before it can be commercialized. The Phase 3 efficacy numbers everyone quotes come from company press releases, not peer-reviewed journals. Psilocybin remains Schedule I federally, including in Oregon.
The short answer
MAPS says it filed written comments in FDA docket FDA-2026-N-7542 on psychedelic-assisted therapy standards. The filing is real as an announcement; its contents are not public. And the docket cannot change psilocybin's legal status, because FDA ruled that out of scope in writing.
On 20 October 2026, MAPS published a post titled "MAPS and Founder Rick Doblin Submit Written Comments to FDA on Psychedelic-Assisted Therapy Standards." The post is password-protected. The body text is not readable by the public, which means the actual content of those comments is unverified — by us or by anyone else outside MAPS.
So treat the headline as an announcement, not as a document. What we can read is the docket MAPS filed into, and that is the more useful object anyway.
FDA opened docket FDA-2026-N-7542, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," on 14 July 2026, held a Part 15 public hearing on 14 September, and closed written comments in early October. The notice names four topics: provider training and credentialing, patient safety, access, and data collection and standardization.
It also names what is out of scope: scheduling under the Controlled Substances Act, legalization, and the safety or efficacy of any specific product.
That sentence is the whole story. A comment docket about training standards is not a path to legal access. The thing that could change access is sitting somewhere else entirely — in a rolling new drug application and a DEA rescheduling decision that has not happened.
What FDA asked for, and what it refused to touch
FDA wanted input on how psychedelic therapy would be delivered in supervised, supportive settings. It explicitly excluded CSA scheduling, legalization, and product-specific safety and efficacy from the request.
The Federal Register notice is here, and it is short enough to read yourself: https://www.federalregister.gov/documents/2026/07/14/2026-14155/considerations-for-potential-future-therapeutic-use-of-psychedelic-drugs-public-hearing-request-for
A small housekeeping discrepancy worth noting because it tells you something about how carefully this was run: the Federal Register metadata lists the comment close date as 6 October 2026, while the notice text and several secondary reports say comments closed at 11:59 p.m. ET on 5 October. Call it early October and move on.
The hearing itself was held 14 September 2026 at FDA's White Oak campus, hybrid format, co-hosted with federal partners. Psychedelic Alpha's account — the most specific one we read — reports roughly 80 speakers with two-minute slots, about 300 people in person and around 1,000 on livestream, and nine federal panelists drawn from FDA, NIDA, VA, SAMHSA and ARPA-H: https://psychedelicalpha.com/news/no-questions-asked-fdas-psychedelics-public-hearing/
Of those nine panelists, only FDA's Marta Sokolowska spoke, delivering prepared remarks. No panelist asked a single question. That was Psychedelic Alpha's central criticism, and it is a fair one. A listening session where the officials do not ask anything is a procedural box, not a dialogue.
Kevin Sabet was the one outright critic among speakers, citing small samples and methodological problems. Compass Pathways had a speaking slot and did not use it. Psychedelic Alpha also reports it understands a shared class-wide REMS is "very unlikely for now" — that is reporting on what the outlet understands, not an FDA statement, and we have seen nothing from FDA either way.
Separately, and more consequentially for sponsors: FDA finalized its Level 1 guidance *Psychedelic Drugs: Considerations for Clinical Investigations* in July 2026, finalizing the June 2023 draft. Guidance documents are nonbinding. They describe FDA's current thinking; they do not create obligations or rights. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations
What MAPS has actually documented
MAPS's readable 17 September release says it attended the hearing and planned to submit testimony on systems readiness, therapist training and patient access, with quotes from Co-Executive Directors Betty Aldworth and Ismail L. Ali. Doblin is named in the October headline; we could not confirm his role in the filing.
Here is the verifiable MAPS record, published 17 September 2026: https://maps.org/2026/09/17/maps-attends-historic-fda-hearing-on-psychedelics/
In it, MAPS says it attended the hearing and *planned* to submit written testimony on systems readiness, therapist training, and patient access. The quotes come from Co-Executive Directors Betty Aldworth and Ismail L. Ali, J.D. Aldworth: "an approved pathway isn't the same as an accessible one." Ali warns that without licensing pathways, insurance billing codes and community infrastructure, "it will be the most vulnerable populations who will once again be left behind."
That is a reasonable argument, and it is the argument the docket was nominally built to hear. MAPS also says it shared its open-science Ibogaine Investigator's Brochure with HHS, FDA and VA.
Three things we will not pretend to know:
- What the comments say. The October post is password-protected. We could not retrieve the filing from regulations.gov either.
- Rick Doblin's contribution. He is named in the October headline. The September release quotes only Aldworth and Ali. We are not attributing anything to Doblin beyond the headline.
- Why a filing is announced on 20 October when comments closed around 5–6 October. Could be a late-posted announcement of a timely filing. Could be a late comment. We do not know, and guessing in print is how bad facts get born.
For what it is worth, we also could not establish a final comment count. Psychedelic Alpha noted 85 as of the hearing date.
The policy machinery this docket sits inside
Executive Order 14401 and three FDA National Priority Vouchers have accelerated psychedelic review timelines. Neither approves anything, and the order's rescheduling language applies only to products ultimately approved as drugs.
Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," was signed 18 April 2026: https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/
Read what it actually does. It directs FDA to issue Commissioner's National Priority Vouchers to qualifying Breakthrough-designated psychedelics. It directs FDA and DEA to build a Right to Try access pathway, including Schedule I handling authorizations. It directs HHS and ARPA-H to allocate at least $50 million to partner with states on psychedelic programs. And it directs DOJ to begin and complete rescheduling review for Schedule I products that finish Phase 3 — but only for products ultimately approved under section 505 of the FD&C Act, and only "if appropriate under 21 U.S.C. 811."
The order mentions ibogaine by name. It does not mention psilocybin. It creates no enforceable rights and approves nothing.
On 24 April 2026, FDA awarded National Priority Vouchers to three psychedelic programs: Compass Pathways (psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD). Reporting from Fierce Biotech and STAT notes the vouchers compress review from roughly 10–12 months to 1–2 months, and that FDA staff and lawmakers have criticized White House involvement in the voucher decisions: https://www.statnews.com/2026/04/24/trump-psychedelic-drugs-fda-priority-review-mental-health-treatment/
Faster review is not the same as a better dossier. Compressing a review window compresses the time available to scrutinize exactly the safety signals discussed below.
The evidence tier on the drug at the regulatory door
COMP360's Phase 3 results are human randomized controlled trials — but they exist only as sponsor press releases and conference posters, not peer-reviewed papers. The headline effect is a 3.8-point MADRS difference against a 1 mg active comparator.
Tier: human Phase 3 RCT, sponsor-reported, not peer-reviewed. That last clause is the single most important caveat in this article.
COMP006 (Compass press release, 17 February 2026): randomized, double-blind Phase 3 in treatment-resistant depression; 581 participants dosed (25 mg n=296, 10 mg n=142, 1 mg n=143), two doses three weeks apart. Primary endpoint at Week 6 was change in MADRS (see /glossary/madrs) for 25 mg versus 1 mg — a low active comparator, not placebo. Result: −3.8 points (95% CI −5.8 to −1.8), p<0.001.
Then read the response figure carefully: 39% of the 25 mg arm achieved a ≥25% MADRS reduction. The conventional threshold for antidepressant response is ≥50%. A lower bar produces a higher number.
Safety, as reported: six treatment-emergent serious adverse events in six participants (2%). One SAE of suicidal behavior, which occurred in the 1 mg arm. The data safety monitoring board found "no evidence of a clinically meaningful imbalance" in suicidality.
26-week data (press release, 7 July 2026): benefit held through Week 26, with 25 mg separated from 1 mg through the blinded period; about 30% of Week-6 responders reached remission after retreatment in Part B. SAEs over 26 weeks were similar across arms — 6.3% (1 mg) versus 5.7% (25 mg). Common adverse events: nausea, headache, anxiety, visual hallucinations.
COMP005, the earlier Phase 3 with a single 25 mg dose against placebo, reported a −3.6 MADRS difference at six weeks (95% CI −5.7 to −1.5, p<0.001), with 25% meeting the clinically meaningful threshold.
None of COMP005 or COMP006 has been published in a peer-reviewed journal. No independent reviewers have gone through the full datasets in public.
The regulatory position comes from Compass's own Form 10-Q for the period ending 30 June 2026: FDA "granted our request for a rolling review of our NDA, which is ongoing"; COMP360 "must be rescheduled before commercializing COMP360 psilocybin in the U.S."; cash of $433.3 million, runway "into 2028." https://www.sec.gov/Archives/edgar/data/0001816590/000181659026000058/cmps-20260630.htm
Late-September public statements put rolling NDA completion on track for Q4 2026, with a standard 60-day acceptance period after that, and a possible launch in H1 2027 contingent on both FDA approval and DEA rescheduling. There is no confirmed PDUFA date and no confirmed NDA completion.
On MDMA: Psychedelic Alpha reported on 9 August 2026 that Resilient Pharmaceuticals (formerly MAPS PBC, then Lykos) quietly resubmitted its MDMA-for-PTSD application; MAPS responded the next day. The company has not publicly confirmed it, the sourcing is anonymous, and no PDUFA date is public. The original application received a complete response letter on 9 August 2024.
What the state programs already show — and what is legal where
Oregon's prospective cohort of 346 clients shows large symptom reductions and real harms, including 1.2% with serious behavioral reactions and 10% reporting HPPD symptoms at one month. Psilocybin remains Schedule I federally, including in Oregon.
While FDA collects comments, two states are already delivering supervised psilocybin sessions, and the data is starting to arrive.
Tier: prospective observational cohort, uncontrolled. Korthuis et al., *JAMA Network Open*, 19 August 2026, followed 346 adults across 24 of Oregon's 26 active service centers, with 83 facilitators, enrolled November 2024 to March 2026. Mean dose 31.9 mg; 44.2% psychedelic-naive; 90.2% retention at three months. Moderate-to-severe depression fell from 42.2% to 16.5% (RR 0.40, 95% CI 0.32–0.50), anxiety from 45.1% to 13.2%, PTSD symptoms from 48.0% to 16.8%. https://doi.org/10.1001/jamanetworkopen.2026.30608
The harms, which got far less coverage: four participants (1.2%) had serious behavioral reactions requiring medical attention — all psychedelic-naive, all seeking treatment for mental health — including one violent reaction during a session requiring hospital transport. Thoughts of dying or suicide: 1.0% at one week, 1.9% at three months. Past-30-day HPPD symptoms in 10.0% at one month and 8.7% at three months, one with significant distress.
The authors are explicit that an uncontrolled design cannot establish causation, that the sample is roughly 5% of Oregon clients, and that facilitator and participant adverse-event reports often diverged. A correction was issued 22 September 2026 on variable coding; the authors say safety and mental-health findings are unaffected. One author discloses Atai Life Sciences fees.
Tier: preprint, not peer reviewed. Thompson et al., medRxiv, 12 August 2026: retrospective data on 2,363 people at Oregon and Colorado licensed centers. At two weeks, PHQ-9 −49%, GAD-7 −51%. Two findings worth sitting with: symptom change did not differ between doses ≤30 mg and >30 mg, and change correlated only weakly with mystical-experience scores. The authors flag "evidence of possible risk of increased suicidality" and say more robust monitoring is needed. The study was co-sponsored by Althea PBC, whose founders and employees are among the authors.
The legal picture, which the docket does not touch:
- Federal: psilocybin is Schedule I under the Controlled Substances Act, including in Oregon, as Oregon's own health authority states.
- Oregon: adults 21+, no prescription, referral or diagnosis required; a mandatory preparation session with a licensed facilitator; consumption only at a licensed service center with a facilitator present. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-What-are-Psilocybin-Services.aspx As of early February 2026: 11 manufacturers, 1 testing lab, 23 service centers, 389 licensed facilitators. See /legal-status/oregon.
- Colorado: healing centers, cultivators and labs licensed by the Department of Revenue's Natural Medicine Division; facilitators by DORA. First healing center license issued April 2025. Current counts change weekly — check dnm.colorado.gov/healing-centers rather than any article, including ours. See /legal-status/colorado.
- New Mexico: SB 219, the Medical Psilocybin Act, effective 20 June 2025, is a medical model — diagnosed qualifying condition, administration by a New Mexico-licensed health care provider in an approved clinical setting. Statutory implementation deadline is 31 December 2027; producer permit applications opened 17 August 2026. See /legal-status/new-mexico.
A comparison of the two operating models: /vs/oregon-vs-colorado-psilocybin-therapy.
PsyBear takeaways
A comment docket on training standards is not a legal change, the Phase 3 data is still unpublished, and psilocybin is Schedule I everywhere in the U.S. Screening and interactions matter more to your personal risk than any of this.
1. The announcement is verifiable; the comments are not. MAPS's 20 October post exists and is dated. It is password-protected. Anyone telling you what MAPS argued to FDA is either inside MAPS or guessing.
2. The docket cannot reschedule anything, because FDA said so. Scheduling, legalization, and product-specific merits were ruled out of scope in the Federal Register notice. Training standards and billing infrastructure are worth arguing about — Aldworth's "an approved pathway isn't the same as an accessible one" is the right frame — but that argument is downstream of an approval nobody has yet.
3. A hearing where no panelist asks a question is a thin signal. Nine federal panelists, one speaker, zero questions. We found no FDA statement on next steps after the docket closed. The reporting that a class-wide REMS is unlikely "for now" is reporting.
4. The Phase 3 numbers are press releases. Human RCT design, yes. Peer-reviewed publication, no. A −3.8 MADRS difference against a 1 mg active comparator, with response defined at ≥25%, is a modest effect described generously. Hold it loosely until a journal and independent reviewers have seen the data.
5. Approval alone changes nothing at the pharmacy. Compass's own SEC filing says COMP360 must be rescheduled before U.S. commercialization. Any H1 2027 launch depends on FDA *and* DEA. No PDUFA date is public.
6. The real-world safety data is the part to actually read. In Oregon's 346-person cohort, 1.2% had serious behavioral reactions needing medical attention — all psychedelic-naive, all seeking mental health treatment — and 10% reported HPPD symptoms at one month. That is from the same study people cite for the benefit numbers. See /guides/long-term-effects-of-psilocybin.
7. Interactions outrank policy in your personal risk calculation. Lithium is the serious one: Nayak and colleagues, *Pharmacopsychiatry* 2021, found seizures reported in 47% of 62 lithium-plus-psychedelic online reports versus 0 of 34 lamotrigine reports (https://doi.org/10.1055/a-1524-2794). That is retrospective analysis of self-reported internet reports — weak evidence, and the authors call the conclusion provisional — but it is a signal nobody should test personally. See /guides/psilocybin-and-lithium, /guides/psilocybin-and-ssris, /guides/psilocybin-and-maois, and /guides/psilocybin-drug-interactions. SSRI and SNRI interaction evidence is weaker and conflicting: survey work suggested attenuated effects, experimental work has not supported it.
8. If you are going ahead anyway, the container is the variable you control. Preparation, screening, setting, support, integration: /guides/safe-trip, /guides/trip-preparation, and /dosage. We do not publish dosing instructions beyond those pages.
Psilocybin is a Schedule I controlled substance under U.S. federal law, including in Oregon and Colorado. No FDA-approved psilocybin product exists as of 26 October 2026. This article is education and commentary on regulatory documents and published research, not medical or legal advice. Psilocybin is contraindicated for people with personal or family histories of psychosis or bipolar disorder, and can interact dangerously with psychiatric medication — particularly lithium. Talk to a clinician. Do not buy controlled substances from unlicensed sellers.
Key Takeaways
FDA's docket FDA-2026-N-7542 asked for input on provider training and credentialing, patient safety, access, and data standardization for psychedelics used in supervised settings. The notice says, in writing, that scheduling under the Controlled Substances Act, legalization, and the safety or efficacy of any particular product are out of scope. So a comment filing — including MAPS's, whose contents are behind a password and therefore unverifiable — moves the standards conversation, not the legal status of anything. Meanwhile the thing that could actually change access is Compass Pathways' rolling NDA for COMP360 psilocybin, which the company's own SEC filing says must be rescheduled by DEA before it can be commercialized. The Phase 3 efficacy numbers everyone quotes come from company press releases, not peer-reviewed journals. Psilocybin remains Schedule I federally, including in Oregon.
FAQ
- Does FDA docket FDA-2026-N-7542 make psilocybin legal?
- No. The Federal Register notice explicitly puts scheduling under the Controlled Substances Act, legalization, and the safety or efficacy of specific products out of scope. The docket requested input on provider training and credentialing, patient safety, access, and data standardization for psychedelics used in supervised, supportive settings. Psilocybin remains Schedule I under federal law, including in Oregon.
- What did MAPS say in its written comments to FDA?
- Unknown. MAPS's 20 October 2026 post announcing the submission is password-protected, so the contents are not publicly readable. MAPS's earlier 17 September release said it attended the hearing and planned to submit testimony on systems readiness, therapist training, and patient access, with quotes from Co-Executive Directors Betty Aldworth and Ismail L. Ali, J.D. Rick Doblin is named in the October headline; we could not confirm his specific contribution.
- Has the COMP360 psilocybin Phase 3 data been peer reviewed?
- No. COMP005 and COMP006 results exist as sponsor press releases and conference posters, not journal articles. COMP006 reported a 3.8-point MADRS advantage for 25 mg over a 1 mg active comparator at Week 6 (95% CI −5.8 to −1.8, p<0.001), with 39% of the 25 mg arm achieving a ≥25% MADRS reduction — a lower threshold than the ≥50% normally used to define antidepressant response.
- If FDA approves COMP360, can you get it at a pharmacy immediately?
- No. Compass Pathways' own Form 10-Q for the period ending 30 June 2026 states that COMP360 must be rescheduled before it can be commercialized in the U.S. The rolling NDA was described in late September 2026 as on track for Q4 2026 completion, with a 60-day acceptance period after that and a possible H1 2027 launch contingent on both FDA approval and DEA rescheduling. No PDUFA date is public.
- What harms did the Oregon psilocybin study report?
- In the prospective cohort by Korthuis et al. (JAMA Network Open, 19 August 2026, n=346), four participants (1.2%) had serious behavioral reactions requiring medical attention — all psychedelic-naive and all seeking treatment for mental health conditions — including one violent reaction during a session requiring hospital transport. Thoughts of dying or suicide were reported by 1.0% at one week and 1.9% at three months, and 10.0% reported past-30-day HPPD symptoms at one month. The design is uncontrolled and cannot establish causation.
- Is it safe to take psilocybin while on lithium?
- Nayak and colleagues (Pharmacopsychiatry, 2021) found seizures reported in 47% of 62 online reports describing lithium combined with a classic psychedelic, versus 0 of 34 lamotrigine reports. That is retrospective analysis of self-reported internet reports, not a controlled study, and the authors call the conclusion provisional — but it is the most serious documented interaction signal in this space. Talk to a clinician; see /guides/psilocybin-and-lithium.